TP53 and neuroendocrine carcinoma: Recent studies have shown that these tumors might actually include 2 heterogeneous subgroups with a different pathogenesis: well-differentiated neuroendocrine carcinomas (WD-NECs) characterized by mutations in MEN1, DAXX, and ATRX genes and poorly differentiated neuroendocrine carcinomas (PD-NECs) characterized by p53 and RB1 mutations probably derived from the neuroendocrine differentiation of adenocarcinomas [8, 11, 12].